ORIC - Oric Pharmaceuticals Inc logo

ORIC

Oric Pharmaceuticals Inc

Rev —top 1%5Y
Hold

Oric Pharmaceuticals develops therapies targeting drug resistance in cancers, focusing on small-molecule treatments like enozertinib for EGFR mutations and rinzimetostat for prostate cancer. The company collaborates with major firms for clinical studies.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $718today

Score Overview

1 Year
Score
Net Growth-8.41%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-80.69%
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-90.43%
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Oric Pharmaceuticals Inc fundamental performance

Across Oric Pharmaceuticals Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 73M to -$ 129M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 13.75
1 Year2025-08-12
$ 9.5244.43%
5 Years2021-08-12
$ 19.15-28.20%
All Time2020-04-24
$ 25.77-46.64%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 140M$ 264M
2025$ 0.00-$ 129M$ 281M
2024$ 0.00-$ 127M$ 255M
2023$ 0.00-$ 100M$ 208M
2022$ 0.00-$ 89M$ 206M
2021$ 0.00-$ 77M$ 236M
IPO2020$ 0.00-$ 73M$ 293M

Explore beyond ORIC

You're looking at Oric Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies